COMP <GO>
IRMD vs AORT // REVENUE GROWTH (YOY)
iRadimed Corporation (NASDAQ) VS. Artivion Inc. (NYSE) • 15-METRIC TALLY: IRMD 8
— AORT 4
▲ REVENUE GROWTH (YOY) LEADER: IRMD
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
revenue-growth
14.40%
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
revenue-growth
13.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. AORT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRMD | AORT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.70% | 64.40% | +12.30 | IRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.70% | 4.50% | +33.20 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.9x | 19.3x | +12.60 | AORT | /valuation <GO> |
| Free Cash Flow Yield | 1.57% | 0.07% | +1.50 | IRMD | /fcf-yield <GO> |
| Operating Margin | 31.20% | 7.60% | +23.60 | IRMD | /operating-margins <GO> |
| Net Profit Margin | 26.80% | 2.20% | +24.60 | IRMD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 14.40% | 13.60% | +0.80 | IRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.37% | 0.00% | +1.37 | IRMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.46 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.6 | 46.6 | -20.94 | AORT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.0x | 98.3x | -57.30 | IRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.10B | $1.14B | -$46.5M | AORT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRMD REV | AORT REV | IRMD GROSS % | AORT GROSS % | IRMD FCF | AORT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $83.8M | $441.3M | 76.7% | 64.4% | $17.2M | $839.0K |
| FY 2024 | $73.2M | $388.5M | 76.9% | 64.0% | $17.6M | $11.0M |
| FY 2023 | $65.6M | $354.0M | — | — | $13.5M | $18.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
AORT // BETA —